SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalNNVC - NanoViricides, Inc.


Previous 10 Next 10 
To: old 'n cranky who wrote (12827)9/16/2020 9:48:38 PM
From: HardToFind
   of 12857
 
This lawsuit might even light a fire underneath management to get a drug into human trials...something they have never done before.

Forced into success by a lawsuit...that has to be a rare occurrence. Mind you, the NNVC shareholders will still retain the right to finance Diwan's business aspirations without any obligation to share in the proceeds.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: old 'n cranky who wrote (12827)9/17/2020 1:28:53 AM
From: HardToFind
   of 12857
 
Can one sink a ship that's already on it's way to the bottom of the ocean?

Share RecommendKeepReplyMark as Last Read


To: HardToFind who wrote (12828)9/17/2020 7:12:45 AM
From: old 'n cranky
1 Recommendation   of 12857
 
What lawsuit? No lawsuit is likely.
Two whole months ago a couple of ambulance chasers tried to get a fire started and we haven't heard from them since. Little wonder, they didn't make much of a case to bring a suit.
One said ...
“We’re focused on investors’ losses and whether NanoViricides has accurately represented the work it is doing toward a potential COVID-19 and other treatments,” said Reed Kathrein, the Hagens Berman partner leading the investigation. “We welcome any and all leads that could assist us in protecting investors.”

The other said ......
"The securities investigation concerns whether NanoViricides provided false or misleading information to investors about its activities related to drug development, including a potential treatment for COVID-19."

Do you really think that these folks will be able to show that NanoViricides hasn't accurately represented the work it is doing toward a potential COVID-19 and other treatments, providing false or misleading information to investors about its activities related to drug development in the process?

Even though those things might very well be true they need to be SHOWN and most of these guys don't like to do the necessary work. Besides, if investors don't do everything they can to avoid being misled through their own due diligence they wouldn't seem to have earned the protection of the Court.

It's interesting that the Hagens Berman release says "Relevant Period: Before July 14, 2020".
You know that's not a period, right? They're going to need to determine a claim period. When would you think the appropriate starting date for that might be? Some time in 2005 or whenever the original license was "granted"?

This won't happen: "Forced into success by a lawsuit...that has to be a rare occurrence."
Diwan can't be forced or cajoled or paid into an NNVC success. I don't think it's even part of his plan.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: old 'n cranky who wrote (12830)9/19/2020 4:54:42 PM
From: HardToFind
   of 12857
 
This won't happen: "Forced into success by a lawsuit...that has to be a rare occurrence."Diwan can't be forced or cajoled or paid into an NNVC success. I don't think it's even part of his plan.
You're right on multiple counts. In all likelihood...
  1. There will be no lawsuit.
  2. There will be no success of the company.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: HardToFind who wrote (12831)9/19/2020 5:33:42 PM
From: old 'n cranky
   of 12857
 
Yay me!

:o)

Share RecommendKeepReplyMark as Last Read


From: donpat1/26/2021 12:38:41 PM
   of 12857
 
Medicago

About Us Technologies Discovery Pipeline COVID-19 Media Room Publications Contact CAREERS FR

Leading the way in plant-based vaccine technology

P L A YV I D E O

COVID-19Development Programs


Plant-based Vaccine Technology
Latest news

December 4, 2020
Takashi Nagao appointed President and Chief Executive Officer of Medicago
Read more

November 12, 2020
Medicago and GSK announce start of Phase 2/3 clinical trials of adjuvanted COVID-19 vaccine candidate
Read more

November 10, 2020
Medicago announces positive Phase 1 results for its COVID-19 vaccine candidate
Read more

HOW WE'RE CHANGING THE GAME

Medicago's technologies represent a disruptive approach to vaccines, therapeutic proteins, and disease response.


Plant-Based Manufacturing
This platform brings many advantages, including faster lead time, scalability and versatility.

Learn more

Virus-Like Particles (VLPs)
VLPs mimic the native structure of a virus but do not contain the genetic material.

Learn more

Discovery Platforms
Our unique screening platform accelerates the discovery of new recombinant proteins.

Learn more


WHAT WE'RE WORKING ON
Medicago's proven discovery and development platform is scalable and versatile, allowing us to build a robust and limitless product pipeline.

Coronavirus

Influenza

Rotavirus


https://www.medicago.com/en/






Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: donpat who wrote (12833)1/26/2021 12:49:05 PM
From: donpat
   of 12857
 
Medicago has been privately held since 2013.


https://www.medicago.com/en/about-us/

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: donpat who wrote (12834)1/29/2021 5:45:41 PM
From: mattstat
   of 12857
 
You live?

Share RecommendKeepReplyMark as Last Read


From: HardToFind5/14/2021 11:54:06 PM
   of 12857
 
NNVC is the Dogecoin of biotech!!! Let's get Elon to talk about it on SNL...

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: HardToFind who wrote (12836)5/15/2021 1:06:08 PM
From: Savant
   of 12857
 
Would El say the same thing?

"It's a hustle"?

Share RecommendKeepReplyMark as Last ReadRead Replies (1)
Previous 10 Next 10